Kymab has announced that the Supreme Court of the United Kingdom has held that all of the claims of two patents, often referred to as the ‘Murphy patents’, owned by Regeneron that were asserted against Kymab are invalid. The Court’s decision upholds the February 2016 decision of the High Court trial judge to revoke the claims and reverses the Appeal Court’s determination that they were valid. The Murphy patents sought to cover genetically modified mice containing chimeric human-mouse antibody genes and the human antibodies made using such mice. The patent remains in full force in the US. Learn More